Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC
Adequate pulmonary and cardiac function
Available biopsy of primary tumor with adequate samples
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease
Any prior therapy for lung cancer within 3 years.
Prior treatment with anti-PD-1 or PD-L1 therapies
History or risk of autoimmune disease
Clareo Health | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
